Home LiteratureArticle Details
PMID: 25341010 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

Annual review of medicine ·Vol. 66 ·2015-00-00 ·Pages 509-23

Abdallah CG, Sanacora G, Duman RS, Krystal JH

Abstract

Ketamine is the prototype for a new generation of glutamate-based antidepressants that rapidly alleviate depression within hours of treatment. Over the past decade, there has been replicated evidence demonstrating the rapid and potent antidepressant effects of ketamine in treatment-resistant depression. Moreover, preclinical and biomarker studies have begun to elucidate the mechanism underlying the rapid antidepressant effects of ketamine, offering a new window into the biology of depression and identifying a plethora of potential treatment targets. This article discusses the efficacy, safety, and tolerability of ketamine, summarizes the neurobiology of depression, reviews the mechanisms underlying the rapid antidepressant effects of ketamine, and discusses the prospects for next-generation rapid-acting antidepressants.

Keywords
BDNF biomarker depression mTOR synaptic plasticity
MeSH Terms
Antidepressive Agents/therapeutic use Brain/metabolism Depressive Disorder, Major/drug therapy,metabolism Depressive Disorder, Treatment-Resistant/drug therapy,metabolism Excitatory Amino Acid Antagonists/therapeutic use Glutamic Acid/metabolism Humans Ketamine/therapeutic use Mood Disorders/drug therapy,metabolism Neuronal Plasticity Prefrontal Cortex/metabolism
Chemicals
Antidepressive Agents Excitatory Amino Acid Antagonists Glutamic Acid Ketamine
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Abdallah Chadi G
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06511; email: [email protected] , [email protected] , [email protected] , [email protected].
Sanacora Gerard
Duman Ronald S
Krystal John H
References (109)
109 references, click to expand
  1. Do the dissociative side effects of ketamine mediate its antidepressant effects?
    J Affect Disord. 2014 Apr;159:56-61 PMID: 24679390
  2. Synaptic mechanisms underlying rapid antidepressant action of ketamine.
    Am J Psychiatry. 2012 Nov;169(11):1150-6 PMID: 23534055
  3. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
    Depress Anxiety. 2014 Apr;31(4):335-43 PMID: 24668760
  4. Pharmacological blockade of serotonin 5-HT₇ receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission.
    PLoS One. 2011;6(6):e20210 PMID: 21701689
  5. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.
    Psychopharmacology (Berl). 2003 Sep;169(3-4):247-56 PMID: 12898123
  6. Nuclear calcium signalling in the regulation of brain function.
    Nat Rev Neurosci. 2013 Sep;14(9):593-608 PMID: 23942469
  7. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).
    CNS Neurosci Ther. 2013 Jun;19(6):370-80 PMID: 23575437
  8. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
    Biol Psychiatry. 2012 Oct 1;72(7):555-61 PMID: 22521148
  9. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.
    Nat Rev Neurosci. 2010 Oct;11(10):682-96 PMID: 20842175
  10. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
    Arch Gen Psychiatry. 2008 Feb;65(2):154-64 PMID: 18250253
  11. Homeostatic synaptic plasticity: local and global mechanisms for stabilizing neuronal function.
    Cold Spring Harb Perspect Biol. 2012 Jan 01;4(1):a005736 PMID: 22086977
  12. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
    Biol Psychiatry. 2008 Feb 15;63(4):349-52 PMID: 17643398
  13. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology.
    Mol Psychiatry. 2012 Jul;17(7):664-5 PMID: 22212598
  14. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
    Int J Neuropsychopharmacol. 2014 Feb;17(2):331-6 PMID: 24103211
  15. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.
    Nat Rev Neurosci. 2013 Jun;14(6):383-400 PMID: 23686171
  16. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.
    Neurosci Biobehav Rev. 2009 May;33(5):699-771 PMID: 19428491
  17. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
    Bipolar Disord. 2012 Dec;14(8):880-7 PMID: 22978511
  18. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    J Clin Psychiatry. 2009 Dec;70(12):1662-6 PMID: 19744406
  19. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.
    CNS Drugs. 2010 Aug;24(8):669-93 PMID: 20658799
  20. Cortical energy demands of signaling and nonsignaling components in brain are conserved across mammalian species and activity levels.
    Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3549-54 PMID: 23319606
  21. Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens.
    Transl Psychiatry. 2013 Jun 04;3:e266 PMID: 23736119
  22. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
    Biol Psychiatry. 2013 Aug 15;74(4):250-6 PMID: 22840761
  23. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity.
    Mol Psychiatry. 2010 Mar;15(3):260-71 PMID: 18852698
  24. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression.
    Int J Neuropsychopharmacol. 2012 Sep;15(8):1063-72 PMID: 22040773
  25. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
    Psychiatry Res. 2011 Feb 28;191(2):122-7 PMID: 21232924
  26. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
    Arch Gen Psychiatry. 2010 Aug;67(8):793-802 PMID: 20679587
  27. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Arch Gen Psychiatry. 2006 Aug;63(8):856-64 PMID: 16894061
  28. ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.
    Biol Psychiatry. 2012 Jun 1;71(11):1022-5 PMID: 22169441
  29. Serial infusions of low-dose ketamine for major depression.
    J Psychopharmacol. 2013 May;27(5):444-50 PMID: 23428794
  30. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
    Psychopharmacology (Berl). 2005 Apr;179(1):303-9 PMID: 15309376
  31. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers.
    Am J Psychiatry. 1997 Jun;154(6):805-11 PMID: 9167508
  32. Grand challenges in global mental health.
    Nature. 2011 Jul 06;475(7354):27-30 PMID: 21734685
  33. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?
    Hum Psychopharmacol. 2013 Jan;28(1):87-90 PMID: 23124710
  34. Metabotropic glutamate receptors: physiology, pharmacology, and disease.
    Annu Rev Pharmacol Toxicol. 2010;50:295-322 PMID: 20055706
  35. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.
    Neuropsychopharmacology. 2010 Jun;35(7):1415-22 PMID: 20393460
  36. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
    J Affect Disord. 2013 May;147(1-3):416-20 PMID: 23182590
  37. mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade.
    Int J Neuropsychopharmacol. 2012 May;15(4):429-34 PMID: 22114864
  38. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine.
    Neuropsychopharmacology. 2013 Oct;38(11):2268-77 PMID: 23680942
  39. Acute antidepressant effects of intramuscular versus intravenous ketamine.
    Indian J Psychol Med. 2014 Jan;36(1):71-6 PMID: 24701015
  40. Effects of ketamine in treatment-refractory obsessive-compulsive disorder.
    Biol Psychiatry. 2012 Dec 1;72(11):964-70 PMID: 22784486
  41. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression.
    Pharmacopsychiatry. 1996 Jan;29(1):23-6 PMID: 8852530
  42. A neurotrophic model for stress-related mood disorders.
    Biol Psychiatry. 2006 Jun 15;59(12):1116-27 PMID: 16631126
  43. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.
    Am J Psychiatry. 2005 Feb;162(2):394-6 PMID: 15677610
  44. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism.
    Am J Psychiatry. 2004 Oct;161(10):1776-82 PMID: 15465973
  45. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
    Arch Gen Psychiatry. 2000 Mar;57(3):270-6 PMID: 10711913
  46. Synaptic plasticity: multiple forms, functions, and mechanisms.
    Neuropsychopharmacology. 2008 Jan;33(1):18-41 PMID: 17728696
  47. Mechanisms of synapse and dendrite maintenance and their disruption in psychiatric and neurodegenerative disorders.
    Annu Rev Neurosci. 2010;33:349-78 PMID: 20367247
  48. Repeated S-ketamine infusions in therapy resistant depression: a case series.
    J Clin Pharmacol. 2013 Sep;53(9):996-8 PMID: 23893490
  49. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
    Biol Psychiatry. 2013 Jun 15;73(12):1133-41 PMID: 23726151
  50. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
    Biol Psychiatry. 2014 Jul 1;76(1):40-6 PMID: 24035344
  51. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications.
    Biol Psychiatry. 2008 Sep 15;64(6):527-32 PMID: 18571629
  52. PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN.
    Clin Pharmacol Ther. 1965 May-Jun;6:279-91 PMID: 14296024
  53. REDD1 is essential for stress-induced synaptic loss and depressive behavior.
    Nat Med. 2014 May;20(5):531-5 PMID: 24728411
  54. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
    Science. 2010 Aug 20;329(5994):959-64 PMID: 20724638
  55. Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement.
    Annu Rev Neurosci. 2011;34:89-103 PMID: 21438687
  56. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.
    Arch Gen Psychiatry. 2005 Jun;62(6):593-602 PMID: 15939837
  57. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
    Biol Psychiatry. 2009 Sep 1;66(5):522-6 PMID: 19545857
  58. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.
    J Neurosci. 1997 Apr 15;17(8):2921-7 PMID: 9092613
  59. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    J Affect Disord. 2014 Feb;155:123-9 PMID: 24268616
  60. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.
    Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1155-9 PMID: 21466832
  61. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
    Annu Rev Pharmacol Toxicol. 2014;54:119-39 PMID: 24392693
  62. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.
    Biol Psychiatry. 2009 Feb 15;65(4):289-95 PMID: 18822408
  63. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.
    Neuropsychopharmacology. 2004 Mar;29(3):566-79 PMID: 14627997
  64. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.
    Biol Psychiatry. 2012 Jun 1;71(11):996-1005 PMID: 22036038
  65. Synaptic dysfunction in depression: potential therapeutic targets.
    Science. 2012 Oct 5;338(6103):68-72 PMID: 23042884
  66. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
    Science. 1998 Aug 28;281(5381):1349-52 PMID: 9721099
  67. On the safety and benefits of repeated intravenous injections of ketamine for depression.
    Biol Psychiatry. 2012 Aug 15;72(4):e11-2 PMID: 22502989
  68. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission.
    Nat Rev Neurosci. 2011 Nov 30;13(1):22-37 PMID: 22127301
  69. Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function.
    Mol Cell Neurosci. 2011 Dec;48(4):308-20 PMID: 21600287
  70. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.
    Neuropsychopharmacology. 2007 Oct;32(10):2087-97 PMID: 17356574
  71. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
    Int J Neuropsychopharmacol. 2013 Mar;16(2):301-11 PMID: 22676966
  72. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
    Nature. 2011 Jun 15;475(7354):91-5 PMID: 21677641
  73. From inflammation to sickness and depression: when the immune system subjugates the brain.
    Nat Rev Neurosci. 2008 Jan;9(1):46-56 PMID: 18073775
  74. BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses.
    Neuron. 1998 Sep;21(3):521-30 PMID: 9768839
  75. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    Biol Psychiatry. 2009 Jan 15;65(2):181-4 PMID: 18996507
  76. Antidepressant effects of ketamine in depressed patients.
    Biol Psychiatry. 2000 Feb 15;47(4):351-4 PMID: 10686270
  77. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
    J Psychopharmacol. 2014 Jun;28(6):536-44 PMID: 24699062
  78. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder.
    Nat Med. 2012 Sep;18(9):1413-7 PMID: 22885997
  79. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
    J Clin Psychiatry. 2010 Dec;71(12):1605-11 PMID: 20673547
  80. Control of synaptic strength by glial TNFalpha.
    Science. 2002 Mar 22;295(5563):2282-5 PMID: 11910117
  81. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.
    Behav Brain Res. 2011 Oct 10;224(1):107-11 PMID: 21669235
  82. Ubiquitination in postsynaptic function and plasticity.
    Annu Rev Cell Dev Biol. 2010;26:179-210 PMID: 20604708
  83. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study.
    J Psychopharmacol. 2012 May;26(5):733-7 PMID: 21616979
  84. The Yin and Yang of NMDA receptor signalling.
    Trends Neurosci. 2003 Feb;26(2):81-9 PMID: 12536131
  85. Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4T.
    Magn Reson Med. 2008 Feb;59(2):236-44 PMID: 18228589
  86. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
    JAMA Psychiatry. 2014 Jun;71(6):681-8 PMID: 24740528
  87. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
    Am J Psychiatry. 2006 Nov;163(11):1905-17 PMID: 17074942
  88. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression.
    Pharmacopsychiatry. 2013 Sep;46(6):227-8 PMID: 23846402
  89. Ketamine use: a review.
    Addiction. 2012 Jan;107(1):27-38 PMID: 21777321
  90. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
    Biol Psychiatry. 2012 Jun 1;71(11):939-46 PMID: 22297150
  91. Rapid response with ketamine on suicidal cognition in resistant depression.
    Indian J Psychol Med. 2012 Apr;34(2):170-5 PMID: 23162195
  92. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.
    Neuroscience. 2003;117(3):697-706 PMID: 12617973
  93. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
    Arch Gen Psychiatry. 1994 Mar;51(3):199-214 PMID: 8122957
  94. Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior.
    Neuroscience. 2004;128(4):667-73 PMID: 15464275
  95. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.
    Biol Psychiatry. 2013 Nov 15;74(10):742-9 PMID: 23751205
  96. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Am J Psychiatry. 2013 Oct;170(10):1134-42 PMID: 23982301
  97. Ketamine for depression: where do we go from here?
    Biol Psychiatry. 2012 Oct 1;72(7):537-47 PMID: 22705040
  98. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Arch Gen Psychiatry. 2006 Oct;63(10):1121-9 PMID: 17015814
  99. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
    Int J Neuropsychopharmacol. 2011 Sep;14(8):1127-31 PMID: 21557878
  100. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients.
    Neuropsychopharmacology. 2003 Nov;28(11):2020-8 PMID: 12888778
  101. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
    Neuropsychopharmacology. 2013 Nov;38(12):2475-83 PMID: 23783065
  102. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
    Biol Psychiatry. 2012 Aug 15;72(4):331-8 PMID: 22516044
  103. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex.
    Neuron. 2012 Mar 8;73(5):962-77 PMID: 22405206
  104. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).
    Eur Neuropsychopharmacol. 1997 Feb;7(1):25-38 PMID: 9088882
  105. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.
    Biol Psychiatry. 2011 Apr 15;69(8):754-61 PMID: 21292242
  106. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
    Neuro Endocrinol Lett. 2013;34(4):287-93 PMID: 23803871
  107. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.
    Mol Psychiatry. 2009 Aug;14(8):764-73, 739 PMID: 18982002
  108. A randomized controlled trial of intranasal ketamine in major depressive disorder.
    Biol Psychiatry. 2014 Dec 15;76(12):970-6 PMID: 24821196
  109. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).
    Eur Neuropsychopharmacol. 1997 Feb;7(1):9-24 PMID: 9088881
Article Info
Journal
Annual review of medicine
Abbr.
Annu Rev Med
ISSN
1545-326X
DOI
10.1146/annurev-med-053013-062946
Email
[email protected]
[email protected]
[email protected]
[email protected]
Published
2015-00-00
Epub
2014-00-17
Pages
509-23
Language
English
Region
United States
NLM ID
2985151R
PMCID
PMC4428310
Subset
IM
Grants
NIMH NIH HHS · R01 MH017871 · United States
NIMH NIH HHS · R01 MH081211 · United States
NIMH NIH HHS · MH101498 · United States
NIMH NIH HHS · K23 MH101498 · United States
NIMH NIH HHS · R01 MH105910 · United States
NIMH NIH HHS · MH17871 · United States
NCRR NIH HHS · UL1 RR024139 · United States
NIMH NIH HHS · MH081211 · United States
NIMH NIH HHS · R01 MH093897 · United States
NIMH NIH HHS · R37 MH017871 · United States
NIMH NIH HHS · MH093897 · United States
External Links
PubMed source DOI: 10.1146/annurev-med-053013-062946 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2